Immunotherapy in inoperable stage III non-small cell lung cancer: a review

Article Page

Abstract

The leading cause of cancer-related deaths in the United States continues to be lung cancer. Approximately 25–30% of patients are diagnosed with locally advanced nonsmall cell lung cancer (NSCLC). Concurrent chemoradiation with a platinum-based doublet is the current standard of care for patients with inoperable stage III NSCLC. Unfortunately, only 15–20% of patients treated with definitive chemoradiation are alive at 5 years. Thus, there has been a major unmet need in this area. In this article, we summarize the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III NSCLC, and we also present our perspective on the future directions.

Keywords: immunotherapy, inoperable NSCLC, stage III NSCLC.

Citation: Jain NA, Otterson GA. Immunotherapy in inoperable stage III non-small cell lung cancer: a review. Drugs in Context 2019; 8: 212578. DOI: 10.7573/dic.212578

Contributions: Both the authors did the literature search, wrote the manuscript, and critically edited it. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosure and potential conflicts of interest: Dr Otterson reports grants from Genentech, BMS, Merck, Novartis, Pfizer, Celgene, and Astra Zeneca, and consultant fees from Pfizer, Novartis, Takeda, Amgen, and Novocure, outside the submitted work. Dr Jain declares no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at https://www.drugsincontext.com/wp-content/uploads/2019/05/dic.212578-COI.pdf

Acknowledgements: None.

Funding declaration: There was no funding associated with the preparation of this article.

Copyright: Copyright © 2019 Jain NA, Otterson GA. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0
which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial
use without permission.

Correct attribution: Copyright © 2019 Jain NA, Otterson GA. https://doi.org/10.7573/dic.212578. Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0.

Article URL: https://drugsincontext.com/immunotherapy-in-inoperable-stage-iii-non-small-cell-lung-cancer:-a-review

Correspondence: Gregory A Otterson, MD, Starling Loving Hall, 320 West 10th Avenue, Columbus, OH 43212, USA. greg.otterson@osumc.edu

Provenance: invited; externally peer reviewed.

Submitted: 9 January 2019; Peer review comments to author: 14 February 2019; Revised manuscript received: 17 May 2019; Accepted: 20 May 2019; Publication date: 17 June 2019.

Drugs in Context is published by BioExcel Publishing Ltd. Registered office: Plaza Building, Lee High Road, London, England, SE13 5PT.

BioExcel Publishing Limited is registered in England Number 10038393. VAT GB 252 7720 07.

For all manuscript and submissions enquiries, contact the Editor-in-Chief gordon.mallarkey@bioexcelpublishing.com

For all permissions, rights and reprints, contact David Hughes david.hughes@bioexcelpublishing.com

Download free full text PDF